Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery

Table 2

Cancer drug delivery applications of GAG/HA delivery systems.

Application	Components	Drug	References
Antimitotic delivery in bladder carcinoma cells	Hyaluronic acid (HA) 10–12 KDa	Paclitaxel	[176, 177, 181]
Anti-DNA winding delivery; In CD44 overexpressing colon, breast, esophageal, and ovarian cancer	Hyaluronic acid 200 KDa	Irinotecan	[178, 182]
HA-encapsulated drug delivery for metastatic breast, prostate and colon cancer	Hyaluronic acid ~750 KDa	5-FU, doxorubicin	[185, 186]
Localized delivery in bone disease in cancer	Hyaluronic acid	Bisphosphonate	[187]
Nanoparticle delivery in colon cancer	Chitosan-hyaluronic acid	5-FU	[190, 191]
Peritumoral delivery of nanovectors in head/neck cancer (HNSCC)	Lipid-Hyaluronic acid (1.2–5 MDa)	Mitomycin C	[192]
	Hyaluronic acid	Cisplatin	[183]
Intracellular delivery of polymeric micelles for CD44 and folate receptor overexpressing breast and lung cancer and in cancer stem cells	Folic acid conjugated HA-C18 micelles; Folate linked CS on surfaces of Pluronic 127 nanogels	Paclitaxol, doxorubicin, salinomycin, and; doxorubicin	[199–201]; [123]
Intracellular delivery of CD44 overexpressing cancer (breast, colon, and HNSCC)	HA-nanocarrier	Epirubicin, doxorubicin	[50, 176, 196]
		Paclitaxel, mitomycin C, siRNAs	[202]
Intracellular delivery of nanogels in breast cancer	Doxorubicin cores coated with dextran sulfate (DS 435)-nanoparticles	Doxorubicin	[124]